Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta

Placenta

Volumn 35, Issue 12, 2014, Pages 1043-1048

  Keelan, J A ^a   Pugazhenthi, K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Inflammation; Intrauterine infection; Macrolide; Perfusion; Placenta

Indexed keywords

CREATININE; INTERLEUKIN 6; SOLITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; MACROLIDE; TRIAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DECIDUA; DRUG CLEARANCE; DRUG TRANSPORT; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRIORITY JOURNAL; TIME; TROPHOBLAST; DRUG EFFECTS; FETOMATERNAL TRANSFUSION; METABOLISM; PLACENTA; PREGNANCY;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; INTERLEUKIN-6; MACROLIDES; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; TRIAZOLES; TROPHOBLASTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922325634     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2014.09.009     Document Type: Article

References (51)

1. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2010;8:CD001058.
2. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol 2013;208(3). 221 e1-8.
3. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881-90.
4. Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, et al. The fetal safety of macrolides. Antimicrob Agents Chemother 2013;57(7):3307-11.
5. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf 2012;35(7):589-98.
6. Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos 2011;32(7):389-97.
7. Fietta A, Merlini C, Gialdroni Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997;9(1):23-31.
8. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005;49(6):2372-7.
9. Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003;188(3):714-8.
10. Kiefer L, Rubin A, Mc CJ, Foltz EL. The placental transfer of erythomycin. Am J Obstet Gynecol 1955;69(1):174-7.
11. Heikkinen T, Laine K, Neuvonen PJ, Ekblad U. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br J Obstet Gynaecol 2000;107(6):770-5.
12. Munic V, Kelneric Z, Mikac L, Erakovic Haber V. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 2010;41(1):86-95.
13. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 2004;48(3):809-14.
14. Togami K, Chono S, Morimoto K. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Die Pharm 2012;67(5):389-93.
15. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol 2006;2(1):51-69.
16. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. PLoS Med 2009;6(12):e1000191.
17. Subramaniam A, Abramovici A, Andrews WW, Tita AT. Antimicrobials for preterm birth prevention: an overview. Infect Dis Obstet Gynecol 2012:2012.
18. Mercer B. Antibiotics in the management of PROM and preterm labor. Obst Gynecol Clin North Am 2012;39(1):65-76.
19. Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect 2010;16(11): 1649-55.
20. Flenady V, Hawley G, Stock OM, Kenyon S, Badawi N. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev 2013;12:CD000246.
21. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012;12(5):527-34.
22. Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. Antimicrob Agents Chemother 2014;58(6): 3151-6.
23. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56(5):2739-42.
24. Farrell DJ, Castanheira M, Sader HS, Jones RN. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J Infect 2010;61(6):476-83.
25. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009;53(5):2139-41.
26. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013;57(6):2526-34.
27. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 2011;55(5):1997-2003.
28. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NFkappaB inhibition. J Pharmacol Exp Ther 2013;345(1):76-84.
29. Keelan JA, Kemp MW, Payne MS, Johnson D, Stock SJ, Saito M, et al. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob Agents Chemother 2014;58(1):447-54.
30. Pereira DE, Degenhardt TP, Fernandes P. Comparison of CEM-101 metabolism in mice, rats, monkeys and humans. In: ICAAC Conference; 2010. Sept 12-15, Boston.
31. Thorsrud B. CEM-101: an oral gavage study for effects on embryo-fetal development in rats with a toxicokinetic evaluation. Mattawan, Michigan: MPI Research, Inc; 2011. p. 1-638. 1410-006.
32. Miura Y, Payne MS, Keelan JA, Noe A, Carter S, Watts R, et al. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother 2014;58(9):5413-20.
33. Carter AM. Animal models of human placentationea review. Placenta 2007;28(Suppl. A):S41-7.
34. Myren M, Mose T, Mathiesen L, Knudsen LE. The human placentaean alternative for studying foetal exposure. Toxicol In Vitro 2007;21(7):1332-40.
35. Balakrishnan B, Henare K, Thorstensen EB, Ponnampalam AP, Mitchell MD. Transfer of bisphenol A across the human placenta. Am J Obstet Gynecol 2010;202(4). 393 e1-7.
36. Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther 2011;90(1):67-76.
37. Mathiesen L, Mose T, Morck TJ, Nielsen JK, Nielsen LK, Maroun LL, et al. Quality assessment of a placental perfusion protocol. Reprod Toxicol 2010;30(1): 138-46.
38. Eaton BM, Browne MJ, Contractor SF. Maternal to fetal movement of creatinine as a measure of perfusion efficiency and diffusional transfer in the isolated human placental lobule. Placenta 1985;6(4):341-6.
39. Cook JG. Creatinine assay in the presence of protein. Clin Chim Acta 1971;32(3):485-6.
40. Aye IL, Waddell BJ, Mark PJ, Keelan JA. Oxysterols exert proinflammatory effects in placental trophoblasts via TLR4-dependent, cholesterol-sensitive activation of NF-kappaB. Mol Hum Reprod 2012;18(7):341-53.
41. Keelan JA, Wong PM, Bird PS, Mitchell MD. Innate inflammatory responses of human decidual cells to periodontopathic bacteria. Am J Obstet Gynecol 2010;202(5). 471 e1-11.
42. Redinbaugh MG, Turley RB. Adaption of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions. Anal Biochem 1986;153:267-71.
43. Singh AT, Dharmarajan A, Aye IL, Keelan JA. Ceramide biosynthesis and metabolism in trophoblast syncytialization. Mol Cell Endocrinol 2012;362(1-2):48-59.
44. Witt A, Sommer EM, Cichna M, Postlbauer K, Widhalm A, Gregor H, et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003;188(3):816-9.
45. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Resp J 2012;42(1):239-51.
46. Fernandes P, Hashiguchi T, Fujii M, Yoneyama H. Solithromycin reduces inflammation in mice caused by bleomycin-induced lung injury. Am J Crit Care Med 2014;189(Abstract 42):A6586.
47. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013;169(5):1024-34.
48. Benachour N, Aris A. Toxic effects of low doses of bisphenol-A on human placental cells. Toxicol Appl Pharmacol 2009;241(3):322-8.
49. Vahakangas K, Myllynen P. Experimental methods to study human transplacental exposure to genotoxic agents. Mutat Res 2006;608(2):129-35.
50. Sharp AN, Heazell AE, Crocker IP, Mor G. Placental apoptosis in health and disease. Am J Reprod Immunol 2010;64(3):159-69.
51. Keelan JA, Khan S, Yosaatmadja F, Mitchell MD. Prevention of inflammatory activation of human gestational membranes in an ex vivo model using a pharmacological NF-kappaB inhibitor. J Immunol 2009;183(8):5270-8.